Search Results - monoclonal+antibody

7 Results

Sort By:

Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer

Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development, where it is known as physiological angiogenesis, and during the growth of solid tumors, where it is known as pathological angiogenesis. CD276, also known as B7-H3, is a cell surface tumor endothelial...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Steven Seaman, Saurabh Saha, Xaioyan Zhang, Dean Welsch, Gary Decrescenzo

Keywords(s): Antibody Drug Conjugate (ADC), B7-H3, CANCER, CD276, Dimitrov, immuno-oncology, Immunotherapy, Monoclonal Antibody

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents

Abstract: The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing this technology. The type 1 insulin-like growth factor (IGF) receptor (IGF1R) is over-expressed by many tumors and mediates proliferation, motility, and protection from apoptosis. Agents that...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Qi Zhao, Zhongyu Zhu

Keywords(s): Dimitrov, IGF-I, IGF-II, insulin-like growth factor, Monoclonal Antibody

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276

Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development (physiological angiogenesis) and during the growth of solid tumors (pathological angiogenesis). CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor...

Published: 5/22/2024 | Inventor(s): Brad St. Croix, Yang Feng, Steven Seaman

Keywords(s): ADC, antibody drug conjugate, B7-H3, CD276, Immunotherapy, Monoclonal Antibody, St. Croix

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia

Abstract: Fms-like tyrosine kinase 3 (FLT3) is a cytokine receptor which belongs in the receptor tyrosine kinase class III. FLT3 is expressed on the surface of many hematopoietic progenitor cells and plays an important role in hematopoietic stem/progenitor cell survival and proliferation. It is often overexpressed in acute lymphoblastic leukemia (ALL)...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen, Terry Fry, Christopher Chien, Haiying Qin

Keywords(s): acute lymphocytic leukemia, acute myeloid leukemia, ALL, AML, CANCER, cancer therapeutic, chimeric antigen receptor (CAR), Flt3, Monoclonal Antibody

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent

Abstract: Biofilms are complex microbial communities, surface attached and held together by self-produced polymer matrices. These matrices are mainly composed of polysaccharides, secreted proteins and nucleic acids. Poly-N-acetyl glucosamine (PNAG) is a highly conserved surface polysaccharide expressed by a range of bacterial, fungal and protozoan...

Published: 5/22/2024 | Inventor(s): Jeffrey Gildersleeve, Joel Temme

Keywords(s): ANTIMICROBIAL, Biofilm, Deacetyleated Poly-N-Acetyl Glucosamine, dPNAG, Gildersleeve, Mab, Monoclonal Antibody, TG10

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Monoclonal Antibodies Targeting Human DNA Polymerase beta, a DNA Repair Enzyme

Available for licensing are monoclonal antibodies targeting human DNA polymerase beta (Pol B). Pol B is a constitutively expressed "housekeeping" enzyme that plays a role in base excision repair (BER), a cellular defense mechanism that repairs DNA base damage and loss. Aberrant Pol B expression is associated with genomic instability indicating that...

Published: 7/25/2024 | Inventor(s): Rajendra Prasad, Samuel Wilson

Keywords(s): AC5XXX, ACXXXX, ANTIBODY, AXXXXX, CC2XXX, CCXXXX, CDXXXX, CXXXXX, DNA, DNA polymerase, DNA polymerase beta, monoclonal, Monoclonal Antibody, monoclonal antibody based assays, polymerase

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Oncology

Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases

Autoimmune inflammatory diseases occur in greater than five percent of the United States population; this disease group includes asthma, multiple sclerosis, rheumatoid arthritis, and lupus. Treatments generally include immunosuppressants or anti-inflammatory drugs, which can have serious side effects; recently, more specific immunomodulatory therapies...

Published: 7/30/2024 | Inventor(s): Francoise Meylan, Yun-Jeong Song, Richard Siegel

Keywords(s): antibodies, ANTIBODY, ANTI-HUMAN, Anti-mouse, Autoimmune, diagnostic, DR3, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Immunomodulation, immuno-modulator, immunomodulatory, INFLAMMATORY, inflammatory disease, IXXXXX, monoclonal, Monoclonal Antibodies, Monoclonal Antibody, Patent Category - Biotechnology, therapeutic, TL1A, tnf, TNFRSF25, TNFSF15, tumor necrosis factor, USES

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Immunology